You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The genome mapping firm had fallen out of compliance with respect to its loan agreement with Innovatus and will prepay $5 million toward the loan principal.
The deal will allow users of MGI's DNBSEQ sequencers to convert previously validated assays to the platform and access Sophia's analytics technology.
With the partnership, the companies aim to help researchers streamline their workflows from sample collection to enrichment to interpretation.
Unlike the Hi-C chromosome conformation assay, the Pore-C technique reveals information that's lost with short-read sequencing.
The two companies had worked closely together since Parabricks spun out of the University of Michigan in 2015 and entered the Nvidia accelerator program.
Computational hardware maker Nvidia has purchased Parabricks, which has applied GPU technology to bring whole-genome sequencing processing time under an hour.
IQvia, the lead investor in this round, will work with BC Platforms to integrate genomic and clinical data in a secure environment to support biomedical research.
Germany's Life & Brain Genomics hopes to streamline sample management and genetic array input for its multi-omics analysis services.
The five-year FDA contract will add support for multi-omics data and various cloud-based analytical and statistical apps on the PrecisionFDA NGS platform.
The San Diego-based genomic analysis firm reported $3.3 million in revenue, driven by growth in North America sales, offset by a decline in international sales.
Nearly 30,000 COVID-19 tests the UK sent to the US came back as void, according to the Telegraph.
Black principal investigators receive less favorable application scores when seeking US National Institutes of Health grants, the Chronicle of Higher Education reports.
New Scientist reports that both RNA and DNA may have been involved in the emergence of life on Earth.
In Nature this week: new Sperm-seq method enables crossover analysis, tumor-informed detection approach for minimal residual disease, and more.